Previous Close | 176.94 |
Open | 174.82 |
Bid | 174.82 x 1000 |
Ask | 188.78 x 1000 |
Day's Range | 174.52 - 180.49 |
52 Week Range | 105.43 - 192.79 |
Volume | |
Avg. Volume | 1,387,450 |
Market Cap | 32.934B |
Beta (5Y Monthly) | 0.82 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.84 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 159.88 |
The (ticker: XBI), which tracks small- and mid-cap biotech stocks, fell 33.7% in the first half of the year, which ended on Thursday. The (IBB), which tracks larger biotech names, fell 22.8%. In a note out early Friday, analysts with Cowen biotechnology team noted that June represented the XBI’s first positive month since last August.
Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive. Related: Merck Shows Takeover Interest In Seagen: WSJ. According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in